Abstract
324 Clinical pharmacokinetics (PK), translational PK/pharmacodynamics (PD), and exposure–adverse events (AEs) relationship of MLN2480, an oral investigational pan-RAF kinase inhibitor
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have